Levodopa prodrug mesylate, compositions thereof, and uses thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/24
A61P-025/00
출원번호
US-0010419
(2011-01-20)
등록번호
US-8193242
(2012-06-05)
발명자
/ 주소
Xiang, Jia-Ning
Dai, Xuedong
Zhou, Cindy X.
Li, Jianhua
Nguyen, Mark Q.
출원인 / 주소
XenoPort, Inc.
대리인 / 주소
Kilpatrick Townsend & Stockton LLP
인용정보
피인용 횟수 :
2인용 특허 :
42
초록
(2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.
대표청구항▼
1. A method of treating Parkinson's disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate. 2. The method of claim 1, wherein the (2R)-2-phenylca
1. A method of treating Parkinson's disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate. 2. The method of claim 1, wherein the (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate is administered as a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and a therapeutically effective amount of the (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate. 3. The method of claim 2, wherein the pharmaceutical composition is formulated for sustained release oral administration. 4. The method of claim 2, wherein the pharmaceutical composition comprises at least one other diastereomer of 2-phenylcarbonyloxypropyl-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate wherein the diastereomeric purity of the (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate is at least 90%. 5. The method of claim 2, wherein the pharmaceutical composition comprises an L-aromatic amino acid decarboxylase inhibitor. 6. The method of claim 2, wherein the pharmaceutical composition comprises a catechol-O-methyltransferase inhibitor. 7. The method of claim 2, wherein the pharmaceutical composition comprises an L-aromatic amino acid decarboxylase inhibitor and a catechol-O-methyltransferase inhibitor. 8. A method of treating a disease selected from depression, attention deficit disorder, schizophrenia, manic depression, cognitive impairment disorders, restless legs syndrome, periodic limb movement disorders, tardive dyskinesia, Huntington's disease, Tourette's syndrome, hypertension, addictive disorders, congestive heart failure, and excessive daytime sleepiness in a patient, comprising administering to a patient in need of such treatment a therapeutically effective amount of (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate. 9. The method of claim 8, wherein the (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate is administered as a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and a therapeutically effective amount of the (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate. 10. The method of claim 9, wherein the pharmaceutical composition is formulated for sustained release oral administration. 11. The method of claim 9, wherein the pharmaceutical composition comprises at least one other diastereomer of 2-phenylcarbonyloxypropyl-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate wherein the diastereomeric purity of the (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate is at least 90%. 12. The method of claim 9, wherein the pharmaceutical composition comprises an L-aromatic amino acid decarboxylase inhibitor. 13. The method of claim 9, wherein the pharmaceutical composition comprises a catechol-O-methyltransferase inhibitor. 14. The method of claim 9, wherein the pharmaceutical composition comprises an L-aromatic amino acid decarboxylase inhibitor and a catechol-O-methyltransferase inhibitor.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (42)
Metcalf Brian W. (Strasbourg FRX) Jung Michel (Illkirch Graffenstaden FRX), a
상세보기
Saari Walfred S. (Lansdale PA), Antihypertensive amino acid esters.
Dempski Robert E. (Dresher PA) Scholtz Edward C. (King of Prussia PA) Nibbelink Donald W. (Lansdale PA) Reines Scott A. (New Hope PA), Controlled release combination of carbidopa/levodopa.
Budavari John (Watchung NJ) Czaja Robert F. (Scotch Plains NJ) Grabowski Edward J. J. (Westfield NJ) Shukis William F. (Edison NJ) Zambito Arthur J. (Clark NJ), Crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters and process.
Edgren David E. (El Granada CA) Bhatti Gurdish K. (Fremont CA) Carpenter Howard A. (Palo Alto CA), Dosage form for Parkinson\s disease, spasticity and muscle spasms.
Edgren David E. (El Granada) Carpenter Howard A. (Palo Alto) Bhatti Gurdish K. (Fremont) Ayer Atul D. (Palo Alto CA), Dosage form indicated for the management of abnormal posture, tremor and involuntary movement.
Grosswald Ralph R. (Fairfield IA) Anderson Jeffory B. (Springville UT) Andrew Clair S. (Provo UT), Method for the manufacture of pharmaceutical cellulose capsules.
Bckstrm Reijo J. (Helsinki FIX) Heinola Kalevi E. (JrvempFIX) Honkanen Erkki J. (Vantaa FIX) Kaakkola Seppo K. (Helsinki FIX) Kairisalo Pekka J. (Helsinki FIX) Linden Inge-Britt Y. (Helsinki FIX) Mnn, Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.